Launched in 2005, TechnoPhage is an innovative clinical-stage biopharmaceutical company committed to the R&D of new biological molecules in several therapeutic areas. The company focuses on three different technological platforms and develops full product solutions to answer different clinical needs in the fields of infection, neuroscience, ophthalmology, and more recently, oncology. TechnoPhage is focused on increasing its pipeline of proprietary technologies and deriving products.
Bacteriophage product pipeline:
- Chronic ulcers (TP-102)
- Respiratory infection (TP-122)
- Urinary tract infection (TP-164)